Comparison Safety and Efficacy of Basal Insulin Lantus® (Insulin Glargine) vs NPH Insulin in Combination With Oral Antidiabetic Drugs (OADs) in Patients With Diabetes Mellitus, Type 2 (DMT2)

Diabetes Mellitus, Type 2 Clinical Trial

— COBIN 2  

Official title:

Comparison Safety and Efficacy of Basal Insulin Lantus® (Insulin Glargine) vs NPH Insulin in Combination With OADs in Patients With DMT2, Assessed by Continuous Glucose Monitoring System (CGMS). Multicentre, Prospective, Open- Label, Single Arm, Comparative Study in Patients Switched From NPH Insulin to Insulin Lantus®.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00659477
• Other study ID #: LANTU_L_02673
• Secondary ID: EudraCT #: 2007-
• Status: Completed
• Phase: Phase 4
• First received: April 10, 2008
• Last updated: July 29, 2010
• Start date: March 2008
• Est. completion date: June 2009

Study information

• Verified date: July 2010
• Source: Sanofi
• Contact: n/a
• Is FDA regulated: No
• Health authority: Czech Republic: State Institute for Drug Control
• Study type: Interventional

Clinical Trial Summary

Aim of the study is to compare two treatment regimens (insulin Lantus as basal insulin vs insulin NPH) plus oral antidiabetics in type 2 diabetic patients and confirm superiority of insulin glargine. Comparison is focused on: blood glucose (BG) variability of the two treatment regimens, quality of diabetes compensation (HbA1c, FBG/Fasting blood glucose), body weight development, dose of insulin and occurrence of symptomatic hypoglycaemia and other adverse events.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 117
• Est. completion date: June 2009
• Est. primary completion date: June 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Diabetes type 2

• Patients treated NPH insulin with stable dosage of OADs (Oral antidiabetic drugs) for at least 2 months prior to study start and OADs treatment with metformin at least 1,7 g /day in combination with sulfonylurea or glinides.

• Patients must have a HbA1c range of >= 4,5% ( 6,2% DCCT/Diabetes Control and Complication Trials) and <= 8% ( 9,4 % DCCT/Diabetes Control and Complication Trials)

• Ability and willingness to perform continuous glucose monitoring system / CGMS (examination within the study)

• Written informed consent obtained prior to enrollment in the study

• Women are either not of childbearing potential or women of childbearing potential must not be pregnant and must use a reliable contraceptive measure for the duration of the study

Exclusion Criteria:

1. Fasting value C peptide <= 400 pmol/l

2. Active proliferative diabetic retinopathy, as defined by the application of photocoagulation or surgery, in the 6 months before study entry or any other unstable rapidly progressing retinopathy that may require photocoagulation or surgery during the study.

3. Pregnant women or women planning gravidity during clinical study protocol

4. Breast-feeding

5. History of hypersensitivity to the study drugs or to drugs with a similar chemical structure

6. Treatment with systemic corticosteroids in the 3 months prior to study entry and during study and other treatment, that can significantly have impression to glycaemia.

7. Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol

8. Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major disease making implementation of the protocol or interpretation of the study results difficult

9. Impaired hepatic function as shown by Alamine aminotransferase (ALT) and/or Aspartate aminotransferase (AST) greater than three times the upper limit of normal range at study entry

10. Impaired renal function as shown by serum creatinine >/= 133 micromol/L in men and >/= 124 micromol/L in women at study entry

11. History of drug or alcohol abuse in the last year

12. Mental condition causing the patient unable to understand the nature, scope and possible consequences of the study

13. Patient unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for follow-up visits and unlikelihood of completing the study

14. Use of insulin glargine outside the scope of the current SPC (Summary of Product Characteristics)

16. Patients included in other clinical studies

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2

Intervention

Drug:
• insulin glargine
once daily

Locations

Country	Name	City	State
Czech Republic	Sanofi-Aventis Administrative Office	Praha

Sponsors (1)

Lead Sponsor	Collaborator
Sanofi

Country where clinical trial is conducted

Czech Republic, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The change in blood glucose variability		before start with insulin glargine treatment and at the end of the study	No
Secondary	Occurrence of adverse events		From signing of informed consent to the end of study	Yes
Secondary	Development of diabetes compensation - fastig blood glucose and HbA1		before starting therapy with Lantus and at the end of study	No
Secondary	Development of weight of patients		Before starting Lantus vs at the end of the study	Yes
Secondary	Comparison of dose of insulins NPH vs Lantus		Before starting Lantus and at the end of the study	No